Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials

201728 citationsReview

Authors

S. R. Walker · Centre for Chronic Disease Control

Paul Komenda · Centre for Chronic Disease Control

Suhail Khojah · University of Manitoba

Wafa A Altuwaijri · University of Manitoba

Kerry Macdonald · University of Manitoba

Brett Hiebert · St. Boniface Hospital

Neil Tangri ·

Abstract

This systematic review of DPP-4 inhibitors in CKD suggests that they reduce HbA1C by about 0.5%. Furthermore, there was not any increase in the risk for significant adverse events. More research is needed to determine the safety and efficacy of DPP-4 inhibitors in CKD.

Topics & Keywords

Diabetes Treatment and Management Peptidase Inhibition and Analysis Pancreatitis Pathology and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Nephron journals/Nephron journals

Volume 136, Issue 2, pp. 85-94

DOI: 10.1159/000454683

Field-Weighted Citation Impact: 2.79